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Abstract 
“Drug-initiated” nitroxide-mediated synthesis of two well-defined, heterotelechelic polymer 
prodrugs (Mn = 1960–5260 g.mol
-1
, Đ = 1.31–1.37) was performed by using the newly-developed 
nitroxide exchange reaction. These polymers comprised at the chain-end, gemcitabine (Gem) as 
anticancer drug and either cyanine 7.5 (Cy7.5) as a near-infrared (NIR) dye suitable for in vivo 
imaging, or biotin (Biot) for cancer cell targeting. These materials were co-nanoprecipitated into 
fluorescently-labeled polymer prodrug nanoparticles of average diameter in the 100–180 nm with 
narrow particle size distribution and variable surface amounts of biotin. Nanoparticles containing 15 
wt.% biotinylated polymer showed superior uptake and the highest cytotoxicity in vitro on A549 
human lung cancer cells. In vivo, on A549 tumor bearing mice, biotinylated nanoparticles showed 
significantly higher efficacy than free Gem and maintained the same anticancer activity than non-
targeted nanoparticles without inducing prohibitive body weight loss. Biotinylated polymer prodrug 
nanoparticles did not result in an improved anticancer activity or significant increase in tumor 
accumulation, which may be the result of either a not optimal biotin surface display and/or 
insufficient affinity towards the target. They however displayed delayed liver accumulation 
compared to non-biotinylated counterparts, suggesting premise of stealth property likely due to the 
hydrophilic tetraethyleneglycol-Biot positioned at the nanoparticle surface. This work showed for 
the first time the applicability of this simple construction method to in vivo imaging and cancer cell 
targeting, and might stimulate the design of new functional materials for biomedical applications. 
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1. Introduction 
Recent advances in anticancer therapy showcased nanomedicines as potentially powerful tools to 
overcome several issues associated with conventional chemotherapy, such as early metabolization, 
rapid excretion and nonspecific biodistribution of conventional drugs.
1,2
 The most widely used 
approach is the physical encapsulation of drugs into nanocarriers (e.g., micelles,
3
 liposomes,
4
 
polymer nanoparticles
5
), which resulted in a wide array of promising achievement and advanced 
clinical trials.
6,7
 Among the different systems, polymers offer notable advantages such as high 
flexibility resulting from potent macromolecular synthetic strategies, great diversity in terms of 
nature, properties and compositions, and easiness of functionalization.
8
 Nonetheless, for successful 
translation to the clinical stage, nanomedicines still need to address important limitations, most 
notably: (i) rather poor drug loadings (DL), which necessitate high concentration of nanocarriers 
that may lead to in vivo toxicity and (ii) the “burst release”, which is the rapid and uncontrolled 
release of drugs post-administration. The prodrug approach,
9
 relying on the covalent linkage 
between the drug and the polymer scaffold, appeared to be a smart way to overcome those 
limitations. The most employed technique to prepare polymer prodrugs, the so-called “grafting to” 
approach, consists in coupling a drug to a preformed polymer, such as poly(N-(2-hydroxypropyl) 
methacrylamide) (HPMA)
10-13
 or many others.
9
 However, this strategy may appear somewhat 
complex as it often resulted in multistep syntheses and tedious purification, and still exhibits rather 
moderate DL. In recent years, the “drug-initiated method”14 was proposed as an alternative to tackle 
these issues. It consists in growing a polymer chain in a controlled manner from a drug-bearing 
initiator and showed several key advantages over other construction methodologies: (i) a few 
synthetic steps with high yields and facilitated purification; (ii) a quantitative incorporation of one 
drug molecule at the extremity of each polymer chain; (iii) a tunable drug loading that can reach 
high values (up to 40 wt.%) by reduction of the polymer chain length and (iv) its applicability to 
virtually any kind of polymer and drug, providing the latter can be functionalized. The “drug-
initiated method” has been performed by reversible-deactivation radical polymerization (RDRP), 
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especially reversible addition-fragmentation chain transfer (RAFT) polymerization
15
 and nitroxide-
mediated polymerization (NMP),
16
 leading to well-defined polymer prodrugs from different 
drug/polymer pairs.
17-25
 The resulting polymer prodrug nanoparticles exhibited high DL, high 
colloidal stability without any additional surfactant, significant in vitro cytotoxicity against various 
cancer cell lines and ability to drastically reduce tumor growth in vivo.  
Another important advantage provided by RDRP techniques is the nearly quantitative 
retention of the controlling agent (i.e., nitroxide for NMP and chain transfer agent for RAFT 
polymerization) at the ω-chain end, whose presence can be capitalized on to further post-
functionalize the polymer with a second biological moiety. Such telechelic polymers are gaining 
broad importance in the biomedical field
26
 and we recently proposed a simple synthetic strategy to 
synthesize heterotelechelic polymer prodrugs by combining the “drug-initiated method” and the 
nitroxide exchange reaction, to position either a drug and UV-Vis fluorescent probe for in vitro 
imaging or two different drugs for combination therapy.
27,28
  
Despite these recent achievements, ability for this new type of nanomedicine to specifically 
target cancer cells
29
 and/or to enable in vivo imaging is crucially lacking.
14
 Such a demonstration 
would certainly provide additional key benefits and flexibility to the “drug-initiated” approach. 
Whereas in vivo imaging allows biodistribution and semi-quantitative appreciation of 
pharmacokinetics of polymer nanoparticles to be determined,
30-33
 their surface functionalization 
with biologically active ligands is recognized as a promising way to promote their selective 
internalization by cancer cells via a receptor-mediated mechanism, thus  increasing therapeutic 
benefits and limiting undesired systemic side effects.
8
  
In this view, we report on the implementation and investigation of both features in the 
“drug-initiated” approach via the development of targeted, fluorescent polymer prodrug 
nanoparticles resulting from the co-nanoprecipitation of two different heterotelechelic polymer 
prodrugs, bearing either a drug and a near-infrared (NIR) dye suitable for in vivo imaging, or a drug 
and biotin as a model ligand for cancer cell targeting (Figure 1). Because we wanted to keep this 
5 
 
system as simple as possible and keep the DL as high as possible, another aim of this study was to 
determine whether simple surface-functionalization with biotin of nanoparticles prepared by the 
“drug-initiated” method was enough to induce an efficient targeting compared to the traditional 
construction approach consisting in positioning the targeting ligand at the surface of PEGylated 
nanoparticles.  
 
 
Figure 1. “Drug-initiated” synthesis of heterobifunctional polymer prodrug nanoparticles by co-
nanoprecipitation of heterobifunctional polymers bearing: (i) gemcitabine (Gem) and cyanine 7.5 
(Cy7.5) or (ii) Gem and tetraethyleneglycol-biotin (TEG-Biot). 
 
2. Materials and Methods 
2.1 Materials 
Gemcitabine (> 98%) was obtained from Carbosynth Limited (UK). Benzotriazol-1-
yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), EDC HCl, N,N-
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diisopropylethylamine (DIPEA), isoprene, 4-(dimethylamino)pyridine (DMAP), 4-carboxy-
TEMPO, 4-amino-TEMPO, biotin (Biot), tetraethyleneglycol (TEG), tetrahydrouridine and human 
serum (H4522) were purchased from Sigma-Aldrich (France) and used as received. Cyanine7.5 
NHS ester was purchased from Lumiprobe (Germany). AMA-SG1,
34
 Gem-AMA-SG1,
17
 Gem-PI-
Rho,
27
 Gem-PI-SG1 (Gem-PI, Gem-PI’)28 and PI-SG1 (PI)27,28 were prepared as described 
elsewhere. All other reactants were purchased from Sigma-Aldrich at the highest available purity 
and used as received. Deuterated chloroform (CDCl3) was purchased from Eurisotop. Dulbecco's 
Phosphate-Buffered Saline (PBS, pH 7.2-7.4) was purchased from ThermoFisher Scientific. All 
other solvents were purchased from Carlo-Erba at the highest grade. Roswell Park Memorial 
Institute (RPMI) 1640 medium was obtained from Gibco (Italy). Fetal bovine serum (FBS) was 
purchased from EuroClone (Italy). N-tert-butyl-N-(1-diethylphosphono-2,2-dimethylpropyl) 
nitroxide (SG1, 85%) was kindly supplied by Arkema. 
 
2.2 Analytical methods 
Nuclear magnetic resonance (NMR) spectroscopy. NMR spectroscopy was performed in 5 mm 
diameter tubes in CDCl3 at 25 °C. 
1
H and 
13
C NMR spectroscopy was performed on a Bruker 
Avance 300 spectrometer at 300 MHz (
1
H) and 75 MHz (
13
C), respectively. The chemical shift 
scale was calibrated based on the internal solvent signals. For nitroxide derivative characterization, 
pentafluoruphenylhydrazine was added in situ and allowed to react before the analysis.
35,36
 
Mass spectrometry. Mass spectra were recorded with a Bruker Esquire-LC instrument. High-
resolution mass spectra (ESI) were recorded on an ESI/TOF (LCT, Waters) LC-spectrometer.  
Size exclusion chromatography (SEC). SEC was performed with two columns from Polymer 
Laboratories (PL-gel MIXED-D; 300 × 7.5 mm; bead diameter 5 mm; linear part 400 to 4 × 10
5
 
g.mol
-1
), a differential refractive index detector (Spectra System RI-150 from Thermo Electron 
Corp.). The eluent was chloroform at 30 °C and at a flow rate of 1 mL.min
-1
 (Waters 515 pump). 
Toluene was used as a flow-rate marker. The calibration curve was based on polystyrene (PS) 
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standards (peak molar masses, Mp = 162–523 000 g.mol
-1
) from Polymer Laboratories. A 
polyisoprene (PI) calibration curve was constructed by converting the PS standard peak molecular 
weights (MPS) to PI molecular weights (MPI) using Mark-Houwink-Sakurada (MHS) constants 
determined for both polymers in CCl4 at 25 °C. For PI, the MHS constants used were KPI = 2.44 × 
10
4
 and αPI = 0.712. For PS, KPS = 7.1 × 10
4
 and αPS = 0.54 (Mw < 16 700 g.mol
-1
) or KPS = 1.44 × 
10
4
 and αPS = 0.713 (Mw > 16 700 g.mol
-1
).
17
 This technique allowed the calculation of the number-
average molar mass (Mn), the weight-average molar mass (Mw) and the dispersity (Mw/Mn, Ð). 
Dynamic light scattering (DLS) and zeta potential. Intensity-averaged nanoparticle diameters 
(Dz) and zeta potentials (ζ) were measured by dynamic light scattering (DLS) with a Nano ZS from 
Malvern (173° scattering angle) at a temperature of 25 °C. The surface charge of the nanoparticles 
was investigated by ζ-potential (mV) measurement at 25 °C after dilution with 1 mM NaCl, using 
the Smoluchowski equation. 
Cryogenic transmission electron microscopy (cryo-TEM). 5 μL of the nanoparticle suspension 
(0.5 mg.mL
-1
) was deposited on a Lacey Formvar/carbon 300 mesh copper microscopy grid (Ted 
Pella). Most of the drop was removed with a blotting filter paper and the residual thin film 
remaining within the holes was vitrified by plunging into liquid ethane. Samples were then 
observed using a JEOL 2100HC microscope. 
 
2.3 Synthesis 
Synthesis of Biot-TEG (2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl 5-(2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanoate). After 15 min of stirring, a solution of biotin (0.500 g, 
2.05 mmol), EDC (0.470 g, 2.46 mmol), DMAP (cat) in DCM (25 mL) was added dropwise to a 
solution of TEG (3.96 g, 20.5 mmol) in DCM (25 mL). The solution was stirred overnight under 
argon at room temperature. The volatiles were evaporated and the crude product was purified by 
flash chromatography (SiO2, DCM:MeOH, 9:1, v:v) to give 0.754 g of biotin-TEG, as an oil. Yield 
= 87%. 
1
H NMR (300 MHz, CDCl3): δ 5.98 (s, 1H), 5.32 (s, 1H), 4.59 – 4.46 (t, 1H), 4.33 (t, 1H), 
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4.24 (q, 2H), 3.81 – 3.57 (m, 14H), 3.23 – 3.08 (m, 2H), 2.92 (dd, 1H), 2.76 (d, 1H), 2.39 (t, 2H), 
1.66 (s, 4H), 1.48 (dd, 2H). MS (ESI+): m/z = 443.3 (M+Na)
+
. Calc. for C18H32N2O7S: 420.19. 
Synthesis of TEMPO-Biot. After 15 min of stirring, a solution of 4-carboxy-TEMPO (0.342 g, 
1.71 mmol), EDC (0.328 g, 1.71 mmol), DMAP (0.017 g, 0.143 mmol) in DCM (5 mL) was added 
dropwise to a solution of biotin-TEG (0.600 g, 1.43 mmol) in DCM (5 mL). The solution was 
stirred overnight under argon at room temperature. Water was added (50 mL) and then extracted 
three times with DCM. The combined organic layers were washed with brine, dried over MgSO4 
and concentrated under reduced pressure. After purification by flash chromatography (SiO2, 
DCM:MeOH, 95:5, v:v), 0.512 g of TEMPO-Biot were obtained as a red-orange oil. Yield: 65%.
 1
H 
NMR (300 MHz, CDCl3): δ 5.84 (s, 1H), 5.35 (s, 1H), 4.56 – 4.47 (t, 1H), 4.33 (t, 1H), 4.23 (m, 
4H), 3.76 – 3.58 (m, 12H), 3.16 (m, 1H), 2.93 (dd, 1H), 2.74 (d, 1H), 2.68 (m, 1H), 2.37 (t, 2H), 
1.85 (d, 2H), 1.70 (m, 6H), 1.54 – 1.42 (m, 2H), 1.33 – 1.07 (m, 12H).MS (ESI+): m/z = 625.8 
(M+Na)
+
. Calc. for C40H49N2O16: 602.31. 
Synthesis of Gem-PI-Biot. In a 7-mL vial were dissolved Gem-PI-SG1 (Gem-PI, 300 mg, 1 eq) 
and TEMPO-Biot (1 eq) in dry pyridine (1 mL). The solution was degassed under argon for 20 min 
before placing the vial in a preheated oil bath at 110 °C and stirring for 16 h. Gem-PI-Biot was then 
precipitated two times in cold methanol and dried under reduced pressure. The purified polymer 
was characterized by SEC. The post-functionalization yield was calculated by 
1
H NMR using the 
following chemical shifts of Biot ( = 4.56 – 4.47, 4.33, 4.23, 3.76 – 3.58, 3.16 and 2.93 ppm) and 
the chemical shifts of aromatic and anomeric proton of Gem ( = 8.26, 7.48 and 6.26 ppm).  
Synthesis of TEMPO-Cy7.5. To a solution of 4-amino-TEMPO (0.033 g, 0.192 mmol) and 
cyanine7.5 NHS ester (0.100 g, 0.128 mmol) in dry DCM (7 mL) was added DIPEA (0.11 mL, 
0.639 mmol) by syringe under argon atmosphere. The reaction was stirred overnight, in the dark 
under argon at room temperature. Water was added (50 mL) and then extracted three times with 
DCM. The combined organic layers were washed with brine, dried over MgSO4 and concentrated 
under reduced pressure. After purification by flash chromatography (SiO2, DCM:MeOH, 96:4, v:v), 
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0.080 g of TEMPO-Cy7.5 were obtained as a green-blue solid. Yield: 86%.
 1
H NMR (300 MHz, 
CDCl3): δ 8.11 (d, 2H), 7.92 (m, 4H), 7.75 (m, 2H), 7.59 (t, 2H), 7.53 – 7.31 (m, 5H), 6.22 – 5.92 
(m, 2H), 4.19 (m, 2H), 3.69 (s, 3H), 3.64 (m, 1H), 2.60 (m, 4H), 2.32 (t, 2H), 2.00 (d, 12H), 1.67 
(m, 14H), 1.32 (d, 12H).
 
MS (ESI+): m/z = 802.5 (M)
+
. Calc. for C54H66N4O2: 802.5. 
Synthesis of Gem-PI-Cy7.5. Briefly, in a 7-mL vial were dissolved Gem-PI-SG1 (Gem-PI’, 300 
mg, 1 eq) and TEMPO-Cy7.5 (1 eq) in dry pyridine (1 mL). The solution was degassed under argon 
for 20 min before placing the vial in a preheated oil bath at 110 °C and stirring for 16 h. Gem-PI-
Cy7.5 was then precipitated two times in cold methanol and dried under reduced pressure. The 
purified polymer was characterized by SEC and 
1
H NMR. The post-functionalization yield was 
calculated by 
1
H NMR using the chemical shifts of aromatic protons of Cy7.5 ( = 8.16-7.32 ppm) 
and the chemical shifts of anomeric proton of Gem ( = 6.39 ppm).  
 
2.4 Nanoparticle preparation  
All nanoparticles were prepared by the nanoprecipitation technique at a concentration of 2.5 
mg.mL
-1
.
37
 Multifunctional nanoparticles for in vivo imaging were prepared by co-nanoprecipitation 
of Gem-PI-Biot (variable), Gem-PI (variable) and Gem-PI-Cy7 (fixed at 10 wt.%) as follows: N0 = 
0:90:10, N15 = 15:75:10, N50 = 50:40:10 and N90 = 90:0:10 (in wt.%), respectively. Similarly, 
multifunctional nanoparticles for internalization experiment were prepared by co-nanoprecipitation 
of Gem-PI-Biot (variable), Gem-PI (variable) and Gem-PI-Rho (fixed at 10 wt.%)
28
 as follows: N0* 
= 0:90:10, N15* = 15:75:10, N50* = 50:40:10 and N90* = 90:0:10 (in wt.%), respectively. Bare PI 
or monofunctional Gem-PI nanoparticles were prepared from the corresponding polymers. Briefly, 
2.5 mg of PI or Gem-PI were dissolved in 0.5 mL of THF and quickly added to 1 mL of MilliQ 
water. THF was evaporated at ambient temperature using a Rotavapor. Intensity-averaged diameter 
(Dz) and zeta potential measurements were carried out in triplicate by DLS. The nanoparticle 
colloidal stability was assessed in water for 55 days. The nanoparticles were kept at 4°C and 
allowed to reach room temperature before each measurement. For in vivo experiment, nanoparticles 
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were concentrated at ambient temperature using a Rotavapor and then adjusted to the right 
concentration by addition of water.  
 
2.5 Gemcitabine release 
The Gem release kinetics was determined as follows. 0.2 mL of nanoparticle suspension (N90) were 
added to 800 μL of human serum supplemented with 200 µg.mL-1 tetrahydrouridine (THU).38,39 The 
mixture was aliquoted (100 μL), incubated at 37 °C and each aliquot withdrawn at different time 
points (1, 2, 4, 8 and 24 h). The different samples were spiked with 10 μL of 10 μM theophylline 
(Internal Standard, IS) before addition of 1 mL of a mixture of acetonitrile:methanol (90:10, v:v) 
and ultracentrifugated (15 000 g, 20 min, 4 °C). The supernatant was then evaporated to dryness 
under a nitrogen flow at 30 °C and the released drug was quantified by reverse-phase HPLC 
following the method described in our previous publication.
28
   
 A similar experiment was conducted in the presence of Cathepsin B. 140 µL of nanoparticle 
suspension (N90) were added to 560 µL of human serum supplemented with 200 µg.mL
-1
 THU. 
The mixture was spiked with 2.5 µL of a Cathepsin B solution (1000 U.mL
-1
), added at t = 0 and 8 
h. The mixture was aliquoted (100 µL), incubated at 37°C and each aliquot withdrawn at different 
time points (0, 1, 8, 24 h). The different samples were spiked with 10 µL of 10 µM theophylline 
(Internal Standard) before addition of 1 mL of a mixture of acetonitrile:methanol (90:10, v:v) and 
ultracentrifuged (15 000 g, 20 min, 4 °C). The supernatant was then evaporated to dryness under a 
nitrogen flow at 30°C. The HPLC analysis was performed under identical experimental conditions 
as described previously. 
 
2.6 Cell lines and cell culture 
Human lung cancer cell line A549 was obtained from the American Type Culture Collection 
(ATCC) and maintained as recommended. Briefly, A549 cells were grown in Roswell Park 
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Memorial Institute (RPMI) 1640 medium. Medium was supplemented with 10% FBS and 2 mM L-
glutamine. Cells were maintained in a humid atmosphere at 37 °C with 5% CO2. 
 
2.7 Fluorescence-activated cell sorting (FACS)  
Uptake of targeted nanoparticles by cancer cells was assessed by flow cytometry. A549 cells (1 × 
10
5
 per well) were seeded in 12-well plates (1 mL per well). After 24 h, cells were treated with 25 
µg.mL
-1
 of nanoparticles (N0*, N15*, N50* and N90*) containing 10 wt.% of Gem-PI-Rho, and a 
variable percentage of Gem-PI-Biot. Plates were maintained at 37 °C for 6 or 24 h, or at 4°C for 6 
h. Afterwards, cells were detached with trypsin/EDTA then washed 3 times with  PBS + 0.02% 
BSA (1 mL), transferred in FACS tubes and run on a BD FACS Aria (BD Biosciences) flow 
cytometer equipped with 488 (excitation) and 633 (emission) nm laser, acquiring 10000 events 
gating out debris and aggregates. Median Fluorescence Intensity (M.F.I.) of each sample was 
recorded. All experiments were repeated independently at least two times (4 replicates per condition 
each) to determine means and SDs. ANOVA two-way with Tukey’s correction post-test was used to 
determine statistical differences. 
 
2.8 In vitro cytotoxicity 
To evaluate the antiproliferative activity of the different compounds tested, cells (4 × 10
3
 per well) 
were seeded in 96‐ well plates. 24 h after seeding, the medium was replaced with medium 
containing serial dilutions of polymer prodrug nanoparticles, control polymers or free drugs for 72 
h. Cell viability was assessed using the CellTiter‐ Glo luciferase‐ based ATP detection assay 
(Promega) following manufacturer's instructions. CellTiter‐ Glo is a homogeneous assay method 
based on the quantification of ATP, an indicator of the number of metabolically active cells. 
Growth inhibitory activity was evaluated at the end of incubation, comparing data for treated versus 
control samples, using Accelrys® Assay Explorer software. The inhibitory concentration 50% 
(IC50) of the treatments was determined from the dose-response curve. All experiments were 
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repeated independently at least two times (4 replicates per condition each) to determine means and 
SDs. 
 
2.9 Animal care and tumor induction  
Six-week-old male athymic CD1 nude mice were purchased from Charles River Italia. All animals 
were housed in appropriate animal care facilities during the experimental period and were handled 
according to the principles of laboratory animal care and legislation in force in Italy (n° 1201/2016-
PR).  200 μL of the A549 cell suspension, equivalent to 5 × 106 cells, were subcutaneously injected 
into nude mice toward the lower portion of the right flank. Tumors were allowed to grow for 20 
days to a volume of at least 100 mm
3
 before initiating the treatment. Tumor length and width were 
measured with calipers, and the tumor volume was calculated using the following equation: Vtumor = 
(length × width
2
)/2.  
 
2.10 In vivo anticancer activity on solid tumor-bearing mice 
Tumor-bearing nude mice were randomly divided into 4 groups of 8 each and all groups received 
five intravenous injections on days 0, 4, 7, 11 and 14 in the lateral tail vein. On days 0 and 4, mice 
were injected with either: (i) glucose 5 %; (ii) Gem at 7 mg.kg
-1
; (iii) N0 nanoparticles at a Gem-
equivalent dose of 7 mg.kg
-1
 and (iv) N15 nanoparticles at a Gem-equivalent dose of 7 mg.kg
-1
. On 
days 7, 11 and 14, mice were injected with either: (i) glucose 5 %; (ii) Gem at 4 mg.kg
-1
; (iii) N0 
nanoparticles at a Gem-equivalent dose of 4 mg.kg
-1
 and (iv) N15 nanoparticles at a Gem-
equivalent dose of 4 mg.kg
-1
. The injected volume was 10 μL.g-1 of body weight. The mice were 
regularly monitored for changes in tumor size and weight. ANOVA two-way with Tukey’s 
correction test was used to determine statistical differences. The tumor growth inhibition (TGI) was 
calculated as follows: TGI (%) = (1 – Vt/Vc) x 100, where Vt and Vc are the mean tumor volume of 
treated and control groups at the end of the study, respectively 
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2.11 In vivo and ex vivo fluorescence imaging 
Images were acquired using the IVIS Lumina LT Series III (PerkinElmer, USA). Excitation was set 
at 745 nm and emission was recovered on the 810-875 nm emission filter. For quantification, a 
region of interest (ROI) was automatically drawn around the mice liver (in vivo studies) or around 
the organs (ex vivo studies). Average radiant efficiency values (threshold of 5 and 30 % for ex vivo 
and in vivo 
images, respectively) were used for quantification.  
In vivo imaging. A549 tumor-bearing nude mice injected with N0 and N15 nanoparticles 
were anesthetized with isoflurane (3%) and placed in ventral position in the IVIS Lumina. In vivo 
fluorescence images were recorded before the beginning of the treatment, at 5 h and 24 h post each 
injection and at the end of the study (EoS, day 34). ANOVA two-way with Tukey’s correction test 
was used to determine statistical differences. 
Ex vivo imaging. Five A549 tumor-bearing nude mice were injected with N0 (n = 2) and 
N15 (n = 3) and subjected to the treatment schedule presented in section 2.10. The mice were 
euthanized 24 h after last injection to visualize ex vivo fluorescence in the different organs (tumor, 
liver, spleen, lung and kidney).  
At day 34 (EoS), all remaining mice were euthanized and ex vivo fluorescence signal in the 
different organs (tumor, liver, spleen, lung and kidney) was recorded. 
 
3. Results and Discussion 
3.1 Design rationale and selection of the building blocks 
Among the different ligands used for active targeting,
8
 biotin (also known as vitamin B7) has been 
widely used as a targeting moiety,
40-43
 due to overexpression of biotin receptors at the surface of 
many cancer cell types.
44
 Although more specific and potent ligands such as antibodies or peptides 
can be used,
8,45
 coupling of such large-size moieties to nanoparticles could be quite laborious, 
difficult to characterize and also harmful to the nanoparticle colloidal stability. In contrast, 
14 
 
synthesis, purification and characterization of polymers functionalized by a small-size ligand such 
as biotin is generally much easier.  
To confer imaging purposes, a near-infrared (NIR) dye, cyanine7.5 (Cy7.5), was selected. 
This dye can be effectively utilized for noninvasive in vivo imaging, due to the emission in the 
“biological transparency NIR window” in the 700-900 nm region,46 which helps overcoming issues 
such as tissue scattering and background absorption at lower wavelength. 
Two heterotelechelic polymer prodrugs were synthesized by “drug-initiated” synthesis of 
gemcitabine-polyisoprene (Gem-PI) by SG1-mediated radical polymerization, followed by 
nitroxide exchange reaction to substitute the terminal SG1 nitroxide by a functional TEMPO 
nitroxide bearing either biotin or Cy7.5. Gem was chosen as a model anticancer drug because of its 
activity against numerous solid tumors
47
 whereas PI appeared as a suitable materials for biomedical 
applications according to its biocompatibility
48
 due to similarity with natural terpenoids and its 
previous safe use in vitro and in vivo.
17,21,23,27
 The presence of SG1 at the  chain-end of NMP-
synthesized polymers can be exploited by diverse techniques
16
 for post-functionalization purposes. 
We recently demonstrated that the nitroxide exchange reaction
49
 was a facile synthetic approach to 
synthesize heterotelechelic polymers bearing two different biological moieties.
28
 This reaction 
presented several benefits compared to alternative routes, such as the absence of catalyst, reactant or 
byproduct, a simplified work-up, almost quantitative yields and stoichiometric amounts of 
functional nitroxides. The driving forces are the formation of a more thermally stable PI-TEMPO 
macroalkoxyamine than PI-SG1.  
  
3.2 Heterotelechelic polymer prodrug synthesis 
AMA-SG1 was functionalized with Gem via PyBOP coupling
17
 and the resulting Gem-AMA-SG1 
was used to initiate the polymerization of isoprene under SG1 control to yield Gem-PI-SG1 (Gem-
PI and Gem-PI’) with Mn,SEC values of 2310 g.mol
-1
 (conv. = 27%) and 4750 g.mol
-1
 (conv. = 
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52%), relatively low dispersities (Đ = 1.22–1.30) and DL of 12 and 6 wt.%, respectively (Scheme 
1b and Table 1).  
 
 
Scheme 1. (a) Synthesis of TEMPO-Biot and (b) heterobifunctional Gem-PI-Biot polymer prodrug 
by “drug-initiated” nitroxide-mediated polymerization (NMP) of isoprene from Gem-AMA-SG1 
alkoxyamine followed by nitroxide exchange from TEMPO-Biot.  
 
In parallel, TEMPO was functionalized with Biot to further perform the nitroxide exchange and 
obtain the desired heterotelechelic polymer Gem-PI-Biot. Note that to increase hydrophilicity to the 
vicinity of Biot and promote its positioning at the surface of the nanoparticles, a TEG spacer was 
inserted between Biot and TEMPO. More specifically, Biot was first reacted with TEG via EDC 
coupling with an overall yield of 87 %, followed by coupling of Biot-TEG with TEMPO with a 
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65% yield (Scheme 1a). Finally, the nitroxide exchange reaction was performed in pyridine at 
110°C on Gem-PI-SG1 (Gem-PI) to give Gem-PI-Biot (Scheme 1b and Table 1), which presented a 
Mn of 1960 g.mol
-1 
and a dispersity of 1.31. Importantly, SEC traces (DRI detector) of the starting 
Gem-PI and the obtained Gem-PI-Biot were almost perfectly overlaid, indicating the absence of 
irreversible chain termination reactions (Figure S1a). The functionalization yield was calculated by 
1
H NMR by comparing the visible protons of Biot ( = 4.56 – 4.47, 4.33, 4.23, 3.76 – 3.58, 3.16 and 
2.93 ppm) and the aromatic and anomeric proton peaks of Gem ( = 8.26, 7.48 and 6.26 ppm) 
giving a Biot/Gem molar ratio of 0.96, indicating quantitative functionalization (Figure S2). This 
result was further supported by disappearance of the characteristic peak associated to the proton in α 
position to the phosphorus atom of SG1 (3.2-3.4 ppm). 
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Scheme 2. (a) Synthesis of TEMPO-Cy7.5 and (b) heterobifunctional Gem-PI-Cy7.5 polymer 
prodrug by “drug-initiated” nitroxide-mediated polymerization (NMP) of isoprene from Gem-
AMA-SG1 alkoxyamine followed by nitroxide exchange from TEMPO-Cy7.5.  
 
Similarly, TEMPO was reacted with Cy7.5 NHS ester, to give TEMPO-Cy7.5 with an overall yield 
of 86 % (Scheme 2a). After nitroxide exchange in pyridine at 110°C from Gem-PI’, the fluorescent 
heterotelechelic polymer Gem-PI-Cy7.5 was obtained (Scheme 2b), with Mn of 5260 g.mol
-1 
and a 
dispersity of 1.37. SEC traces (DRI detector) showed a very slight migration towards higher molar 
masses, likely due to a change in the hydrodynamic volume of the polymer caused by the positive 
charge of Cy7.5 (Figure S1b). By 
1
H NMR, it was possible to calculate the yield of 
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functionalization by comparing aromatic proton peaks of Cy7.5 ( = 8.16-7.32 ppm) and the 
anomeric proton peak of Gem ( = 6.26 ppm). Note that because of signal overlap, it was necessary 
to subtract Gem aromatic proton signals from Cy7.5 aromatic proton signals. A Cy7.5/Gem molar 
ratio close to 1 (0.92) was calculated, which suggested a nearly quantitative functionalization of the 
chain-end by TEMPO-Cy7.5 (Figure S3). This result was also supported by complete disappearance 
of the characteristic signal to the proton in α position to the phosphorus atom of SG1 (3.2-3.4 ppm). 
Bare PI used as control was also synthesized from AMA-SG1 and had a Mn of 2140 g.mol
-1 
and a 
dispersity of 1.18 (Table 1). 
 
Table 1. Macromolecular and Structural Properties of PI-SG1, Gem-PI-SG1, Gem-PI-Biot and 
Gem-PI-Cy7.5 Polymer Prodrugs. 
Prodrug Mn,SEC
a 
(g.mol
-1
) 
Ð
a 
 
Mn,NMR
 
(g.mol
-1
) 
DPn,NMR
e
 Biot/Gem
f 
Cy7.5/Gem
 f
 Drug loading 
(wt.%)
 g
 
PI
h
 2140 1.18 -
 
- - - - 
Gem-PI 2310 1.22 3293
b
 57 - - 11.6 
Gem-PI-Biot 1960 1.31 3780
 c
 42 0.96 - 13.6 
Gem-PI’ 4750 1.30 4580
 b
 58 - - 5.6 
Gem-PI-Cy7.5 5260 1.37 5890
d
 70 - 0.92 5.1 
a 
Determined by SEC, calibrated with PS standards and converted into PI by using Mark-Houwink-Sakurada 
parameters.  
b 
Calculated according to Mn,NMR = (DPn,NMR x MWisoprene) + MWGem-AMA-SG1. 
c 
Calculated according to 
Mn,NMR = (DPn,NMR x MWisoprene) + MWGem-AMA-SG1 – MWSG1 + MWTEMPO-Biot. 
d 
Calculated according to Mn,NMR = 
(DPn,NMR x MWisoprene) + MWGem-AMA-SG1 – MWSG1 + MWTEMPO-Cy7.5. 
e 
Calculated from ratio of areas under the peak at 
6.1-6.3, 7.3-7.5, 8.0-8.2 ppm (aromatic and anomeric proton of Gem) and 5.0-5.5 ppm (vinylic H in isoprene repeat unit 
(1,4-addition), corresponding to ~81% of total isoprene units). 
f 
Calculated by 
1
H NMR (see experimental part). 
g 
Calculated according to MWGem/Mn,SEC. 
h
 conv. = 28%. 
 
3.3 Nanoparticle formulation and drug release 
NIR-emitting, targeted polymer prodrug nanoparticles were prepared at 2.5 mg.mL
-1
 by 
concomitant nanoprecitation of blends composed of Gem-PI-Biot, Gem-PI-Cy7.5 and Gem-PI. By 
varying the initial weight fraction of Gem-PI-Biot (0, 15, 50 and 90 wt.%) and fixing that of Gem-
PI-Cy7.5 (10 wt.%), nanoparticles with increasing amount of Biot were prepared and termed Nx 
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(with x being the weight fraction in Gem-PI-Biot, x = 0, 15, 50 and 90). Bare control nanoparticles 
were prepared from PI and monofunctional polymer prodrug nanoparticles from Gem-PI (Table 2). 
Bare PI nanoparticles had an average diameter of 140 nm, whereas monofunctional Gem-PI 
nanoparticles were smaller (Dz = 99 nm). Adding 10 wt.% of Gem-PI-Cy7.5 during the 
nanoprecipitation almost doubled the size (N0, Dz = 180 nm), whereas the addition of 15 wt.% of 
Gem-PI-Biot led to a substantial decrease of the diameter (N15, Dz = 118 nm). Such variations may 
be explained by the increase of the HLB when Gem-PI-Biot is used (Table S1) and by electrostatic 
repulsions with Cy7.5-functionalized polymers. Further increase of the initial weight fraction of 
Gem-PI-Biot up to 50 and 90 wt.% did not significantly impact the diameter, as Dz = 137 nm for 
N50 and 142 nm for N90. All nanoparticles presented low PSD values ranging from 0.14 to 0.18 
and strongly negative zeta potentials, suggesting high colloidal stabilization, as already seen for PI-
based prodrug nanoparticles.
17,21,23
 N0 and N90 nanoparticles, that exhibit extreme amounts of 
Gem-PI-Biot, were also characterized by cryo-TEM and displayed spherical morphologies and sizes 
in agreement with those determined by DLS (Figure 2a and 2b).  
 
 
 
 
 
Table 2. Characterization of PI, Gem-PI, N0, N15, N50 and N90 Prodrug Nanoparticles. 
Nanoparticle 
Dz
a
 
(nm) 
PSD
a
 

a
 
(mV) 
Drug Loading (wt.%) b 
PI 140 0.15 -62 - 
Gem-PI 99 0.17 -29 11.6 
N0
c
 180 0.16 -37 10.4 
N15
c
 118 0.17 -43 10.6 
N50
c
 137 0.18 -41 11.1 
N90
c
 142 0.14 -34 11.8 
a
 Measured by dynamic light scattering (DLS). 
b 
Calculated according to MWGem/Mn,SEC. 
c
 Containing 10 wt.% 
Gem-PI-Cy7.5. 
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Because each heterobifunctional polymer prodrug is functionalized by a Gem molecule, the overall 
amount of Gem, and therefore DL values, stayed constant whatever the composition of 
nanoparticles obtained by nanoprecipitation of Gem-PI/Gem-PI-Biot/Gem-PI-Cy7.5 blends. It is an 
important feature and a clear advantage of using heterotelechelic polymer prodrugs compared to 
monofunctional materials as DL would have varied if the corresponding monofunctional polymers 
would have been used. 
All nanoparticles were stable with no formation of visible precipitate over time. For 
instance, the long-term colloidal stability of nanoparticles N0, N15 and PI was monitored in water 
and exhibited rather constant average diameters and particle size distributions for at least 55 days 
(Figure 2c). Note that the smaller average diameter of N15 compared to that of N0 is likely due to 
the presence of hydrophilic TEG-Biotin moieties at the surface of the nanoparticles (supported by a 
higher predicted HLB, Table S1), leading to enhanced colloidal stability. Their long-term colloidal 
stability was also assessed in cell culture medium where average diameters were constant at least up 
to 14 days (Figure S4a), whereas their incubation in PBS (pH 7.2-7.4) led to rapid colloidal 
instability (Figure S4b). 
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Figure 2. Representative TEM images of (a) N0 nanoparticles (scale bar = 100 nm) and (b) N90 
nanoparticles (scale bar = 100 nm). (c) Evolution of the intensity-averaged diameters (Dz) and the 
particle size distributions (PSD) measured by DLS in water of nanoparticles PI, N0 and N15.  
 
To study the cellular internalization, a UV-Vis dye like rhodamine B was preferred to Cy7.5 to 
allow compatibility with the filters of the FACS apparatus. Gem-PI-Rho (Mn SEC = 3842, Ð = 1.30) 
was therefore prepared following a similar synthetic route
27
 and blended (10 wt.%) with Gem-PI 
and Gem-PI-Biot prior co-nanoprecipitation to achieve Rho-labeled nanoparticles with variable 
amounts of Biot: N0*, N15*, N50* and N90* (containing 0, 15, 50 and 90 wt.% of Gem-PI-Biot, 
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respectively). Their average size ranged between 169 and 247 nm and presented low PSD in the 
0.15-0.23 range (Table S2). 
To investigate Gem release over time, N90 and Gem-PI were incubated at 37°C in human 
serum to mimic the biological environment. Monofunctional Gem-PI and heterofunctional N90 
nanoparticles released 6.1 and less than 0.5 mol.% of Gem after 24 h, respectively (Figure S5). 
Although incubation of the nanoparticles in the presence of Cathepsin B, one of the relevant 
enzymes for this type of prodrug,
50
 increased the amount of released Gem by almost a of factor 2, it 
stayed rather modest (Figure S5). This result is in agreement with previous Gem release studies 
from heterobifunctional polymer prodrug nanoparticles for combination therapy.
28
 It was indeed 
suggested that such a dual functionalization (compared to a simple one) affected the supramolecular 
organization of the polymer chains during the nanoparticle self-assembly, by altering the placement 
of Gem within the nanoparticles (i.e., on the surface vs in the core) and therefore its release kinetics. 
In fact, given the short polymer chains, it indeed seemed rather unlikely to have both chain-ends 
displayed at the nanoparticle surface. In our case, hydrophilicity of Biot-TEG moiety may promote 
its surface positioning whereas most of the Gem chain-ends would be buried inside the nanoparticle 
core. This hypothesis is supported by the higher HLB value predicted for model Gem-PI-Biot 
compared to model Gem-PI (Table S1). Furthermore, having biotin at the nanoparticle surface is 
mandatory for targeting purposes to achieve its recognition by overexpressed biotin receptors. It is 
also worth noting that Gem release kinetics from Gem-PI and N90 both rapidly reached a plateau. 
It suggested that only Gem present on the nanoparticle surface was cleaved by specific enzymes, 
whereas the high colloidal stability of the nanoparticles prevented further Gem release until 
nanoparticles got disassembled, for instance in vivo as suggested by the significant anticancer 
efficacy of monofunctional polymer prodrug nanoparticles.
17,20
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3.4 Cellular internalization and in vitro cytotoxicity 
Human lung cancer cell line A549 was chosen because of its susceptibility to Gem
17,19
 and because 
of overexpression of biotin receptor
40
 that may allow for biotin targeting to be evaluated.
42,43,51-55
 
Rho-labeled nanoparticles with increasing weight fractions of biotin N0*, N15*, N50* and N90* 
were incubated with A549 cells at different times and temperatures, then Rho fluorescence signal 
was measured by flow cytometry (Figure 3). 
 
 
Figure 3. Cellular internalization of biotinylated N15*, N50* and N90* nanoparticles and non-
biotinylated N0* nanoparticles in A549 cancer cells for 6 h at 4°C and for 6 and 24 h at 37°C. The 
values are the mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. 
 
The results indicated a significantly higher fluorescence intensity from targeted nanoparticles N15*, 
N50* and N90* compared to non-targeted N0* for both time points at 37°C. Even though there was 
no significative difference between all biotinylated nanoparticles N15*, N50* and N90* at 6 h, a 
clear trend after 24 h was noticed in which the lower the amount of biotin, the higher the 
internalization, resulting in N15* having the best cell uptake. This result is in line with a previous 
study on PLA-b-PEG-Biotin nanoparticles whose surface amount of biotin was varied from 0 to 76 
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mol.% and showed the best binding to streptavidin for 19 mol.% biotin.
43
 Detrimental affinity for 
higher amounts of biotin was assigned to hydrophobic interactions between Biot moieties because 
of increased local concentration and/or receptor overbinding. Also, since biotin groups are here 
likely located rather close to the nanoparticle surface, steric hindrance precluding efficient 
ligand/receptor interaction even for high Biot surface amounts cannot be ruled out. When 
nanoparticles were incubated with cells at 4 °C for 6 h, a strong reduction of the fluorescence was 
observed and the signal was negligible, thus suggesting an internalization via an active mechanism, 
likely by endocytosis similarly to comparable biotinylated, polyisoprenoid prodrug nanoparticles.
42
 
The in vitro cytotoxicity at 72 h of free Gem, PI, non-targeted Gem-PI and N0 
nanoparticles, together with targeted N15, N50 and N90 nanoparticles was evaluated on human 
lung cancer cell line A549 by means of an ATP quantification assay (Figure 4). Note that the 
different nanoparticles contained 10 wt. % of Gem-PI-Cy7.5 to mimic the same formulations that 
will be further used in vivo in the next sections. 
 
Figure 4. Cell viability of A549 cells after incubation for 72 h with increasing concentrations of 
free Gem, bare PI, non-targeted Gem-PI and N0, and targeted N15, N50 and N90 nanoparticles. 
The values are the mean ± SD. 
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First, bare PI nanoparticles did not show any toxicity at all tested concentrations, confirming their 
safety and excluding potential toxicity from the carrier. Free Gem showed a very low IC50 of 15 nM, 
whereas all prodrug nanoparticles had higher IC50 values. This is expected due to their prodrug 
nature, thus requiring their cleavage and drug release from the polymer to exert their activity. To be 
noted that Gem is known to be quickly metabolized in vivo,
56
 which fully justified the use of Gem-
based prodrugs to protect the parent drug from early degradation when administered in vivo. As for 
polymer prodrug nanoparticles, Gem-PI and N0 nanoparticles presented almost the same IC50 (1.06 
and 1.02 µM, respectively), thus excluding potential toxicity from the dye. Biotinylated 
nanoparticles N15 had a very similar IC50 of 1.19 µM, whereas increasing the amount of biotin led 
to a decrease in cytotoxicity, as N50 and N90 had an IC50 of 2.02 and 3.92 µM, respectively. This 
trend is in good agreement with two previous observations we made: (i) a much slower Gem release 
when heterobifunctional Gem-PI-Biot are used in place of monofunctional Gem-PI (Figure S5) and 
(ii) a lower cell internalization of nanoparticles when the surface amount of Biot is too high (Figure 
3). Increasing the Gem-PI content at the expense of Gem-PI-Biot likely resulted in higher Gem 
release kinetics, that seemed to be the predominant effect compared to a better cell uptake for 
biotinylated nanoparticles.  
Given internalization and cell viability data, N15 nanoparticles seemed to be the best 
compromise in terms of cell uptake and cytotoxicity. Accordingly, they were chosen to be 
compared to N0 nanoparticles for further in vivo experiments. 
 
3.5 In vivo anticancer activity 
The in vivo anticancer efficacy of targeted N15 and non-targeted N0 nanoparticles was assessed 
against human lung tumor A549 xenograft model in mice after intravenous injections on days 0, 4, 
7, 11 and 15, at a Gem-equivalent dose of 7 mg.kg
-1
 up to day 4, and at a Gem-equivalent dose of 4 
mg.kg
-1
 for the rest of the treatment (see experimental part and Figure 5a). Evolution of the tumor 
volume and body weight of the mice were monitored over a period of 22 days and compared to that 
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of Gem administrated at the same dose and control mice (glucose 5%), while innocuousness of 
control PI nanoparticles has already been demonstrated.
17
 
 
Figure 5. In vivo anticancer efficacy of Gem, control (glucose 5%), N0 and N15 nanoparticles after 
intravenous administration on days 0, 4, 7, 11 and 15, at a Gem-equivalent dose of 7 mg.kg
-1
 up to 
day 4, and at a Gem-equivalent dose of 4 mg.kg
-1
 for the rest of the treatment to A549 tumor 
bearing mice: (a) tumor volume ratio as a function of time; (b) relative body weight change as a 
function of time. The values are the mean ± SEM (n = 8). Statistical differences: (a) ***p ≤ 0.001, 
N15 vs Gem or control; ****p < 0.0001, N0 vs Gem or control; (b) **p < 0.01, N0 vs N15. 
 
After 22 days, untreated- and Gem-treated mice reached a similar tumor volume ratio of 3.7 and 
3.9, respectively, showing the inefficacy of free Gem under this treatment schedule. In contrast, 
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mice treated with polymer prodrug nanoparticles N0 at the same equivalent dose of Gem, led to a 
significant reduction of the tumor growth compared to control experiments, with tumor volume 
ratios reaching a value of 2.4. Such improvement corresponded to a tumor growth inhibition ~40% 
compared to vehicle (control) and Gem-treated mice, which confirmed the beneficial effect of Gem-
PI prodrug nanoparticles over administration of free Gem. Biotinylated nanoparticles N15 showed a 
very similar anticancer efficacy than N0, in excellent agreement with in vitro cell viability 
experiments. It showed that the greater cell uptake observed in vitro did not, also in vivo, prevail 
over the much slower Gem release kinetics resulting from the heterobifunctionalization, and that the 
anticancer activity of heterobifunctional polymer prodrug nanoparticles was maintained. Despite the 
much slower Gem release kinetic, heterobifunctional nanoparticles N15 maintained the same 
anticancer activity than monofunctional prodrug N0, potentially because of the higher uptake but 
also because of competition with free biotin that may attenuate the difference between both types of 
nanoparticles. 
Interestingly enough, biotinylated nanoparticles N15 were advantageous in terms of body 
weight loss compared to N0. Indeed, more than 11 % weight loss was witness at day 12 with N0 
(leading to 2 dead mice after the second injection at day 4, likely because of the CARPA effect),
57,58
 
whereas N15 and control groups ranged from -2 to -5 % weight, with no loss of mice (Figure 5b). 
This would allow for an increase of the dose of N15 and potentially a greater therapeutic index 
compared to non-biotinylated nanoparticles N0. This reduction of toxicity was already noticed for 
other biotinylated nanoparticles.
59
  
 
 
3.6 In vivo and ex vivo fluorescence imaging 
Given nanoparticles N0 and N15 were already tagged with the NIR fluorescent dye Cy7.5, it 
allowed for their in vivo fate and accumulation to be investigated. The advantage of Cy7.5 over 
other imaging options lies on its emission in the far NIR region, which favors higher penetration 
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depth and reduces the possibility of artifacts from biological tissue.
46
 Moreover, this dye is a well-
established imaging agent to visualize tumor on mice model.
60-62
 Mice were imaged before starting 
the treatment at day 0 (PreT), 5 h and 24 h after injection at day 0 (1T), 4 (2T), 7 (3T), 11 (4T) and 
14 (5T) and at the end of the study (EoS). Representative images from N0- and N15-treated mice 
over time are gathered in Figure 6a.  
 
 
Figure 6. (a) In vivo representative images of tumor-bearing mice after intravenous injection of N0 
or N15 nanoparticles. Excitation at 745 nm and emission collection at 810-875 nm (T = treatment, 
Eos = end of study). (b) Fluorescence signal (Average radiant efficiency; 30% threshold) of the 
mice liver injected with N0 and N15 nanoparticles in function of time. The values represent mean ± 
SEM (n = 8). ** p<0.01, ****p<0.0001. 
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As expected, a strong fluorescent signal was detected in the liver all along the monitoring. It is 
indeed well known that non-PEGylated nanoparticles are rapidly captured by the RES system and 
tend to accumulate in the liver.
63
 For both nanoparticles, a strong fluorescence signal was detected 5 
h after each injection, then slightly decreased at 24 h, before increasing again because of the next 
injection. However, a significant difference in terms of liver accumulation was noticed between the 
two nanoparticles up to day 8 (Figure 6). Indeed, accumulation of biotinylated nanoparticles N15 
was found to be 57 % less important than that of N0 24 h after 2T and 32% less important 24 h after 
3T (Figure 6b). At the fourth injection (4T), the amount of both nanoparticles was similar and they 
both underwent elimination once injections were stopped at day 14. This delayed liver accumulation 
for N15 might be explained by a different surface chemistry resulting from preferential positioning 
of TEG-Biot moieties at the nanoparticle surface, compared to N0. Because of the hydrophilicity of 
TEG-Biot and the very short EG chain, one can indeed imagine that such a compound could induce 
a slight stealth effect, like traditional PEG, and thus transiently allowing to escape opsonization and 
macrophage uptake.  
Unfortunately, no clear signal from N0 or N15 could be detected in the region of the tumor, 
neither in ventral nor dorsal position. The circulation time of both nanoparticles was likely too low 
to induce a marked accumulation in tumor cells by the so-called EPR effect and/or biotin-mediated 
targeting.  
All mice were then euthanized at day 34, to study biodistribution and accumulation in the 
major organs. Other mice were also identically treated with nanoparticles N0 or N15 and sacrificed 
24 h after the fifth injection to assess biodistribution right at the end of the treatment (Figure 7a and 
7b). 
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Figure 7. Ex vivo biodistribution of nanoparticles N0 and N15 in the liver (red), spleen (orange), 
lung (purple), kidney (blue) and tumor (brown) 24 h after the last injection (5T, filled bars) or at the 
end of the study (EoS, empty bars). * p<0.05 vs. N0. 
 
In agreement with in vivo imaging, both types of nanoparticles mostly accumulated in the organs of 
the RES system (liver and spleen) in a similar fashion, 24 h after the last injection. A significant 
accumulation was also found in the lung at 24 h post-5T (followed by rapid elimination until EoS), 
whereas a lower amount was found in the kidney, which is explained by the slow renal excretion of 
the nanoparticles (e.g., disassembled/degraded) due to their high colloidal stability.  
As shown by fluorescence signal detected at both time points, nanoparticles N0 and N15 did 
accumulate into the tumors, which is in agreement with anticancer efficacy experiments. 
Interestingly, fluorescence signal found in tumors of N15-treated mice increased compared to that 
of N0-treated mice (5.8 x 10
7
 in radiant efficiency for N0 vs. 7.7 x 10
7
 for N15, that corresponds to 
a 35% increase), thus indicating a slightly better accumulation likely because of biotin surface-
functionalization. Ex vivo biodistribution was also assessed at EoS. Overall, all organs showed a 
decrease in the average radiant efficacy over time due to nanoparticle clearance. Note that 
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elimination from the lung was faster (~87 % for N0 and N15, respectively) compared to the other 
organs (~55 % for the liver, ~50 % for the spleen, ~38 % for the kidney).  
 
4. Conclusion 
To confer imaging and targeting abilities the simplest possible way to nanoparticles prepared by the 
“drug-initiated” method, two heterotelechelic polymers bearing Gem and either biotin for active 
targeting, or cyanine7.5 for in vivo imaging, were successfully synthesized by nitroxide-mediated 
polymerization of isoprene from a Gem-bearing alkoxyamine, followed by the nitroxide exchange 
reaction from a functional TEMPO nitroxide. These materials were well-controlled with nearly 
quantitative functionalization yields. They were then used to successfully prepare fluorescently-
labeled polymer prodrug nanoparticles with variable surface amounts of biotin. Nanoparticles 
containing the lowest amount of biotinylated polymer (15 wt. %) demonstrated superior cancer cell 
uptake, as observed by FACS, and the highest cytotoxicity in vitro against lung cancer cells A549.  
Biotinylated nanoparticles showed significantly higher efficacy than free Gem in vivo on 
human lung tumor A549 xenograft model in mice and displayed analogous anticancer activity than 
non-targeted counterparts, with an average tumor growth inhibition of ~40%. Moreover, non-
targeted nanoparticles led to more than a 10 % body weight loss conversely to biotinylated 
counterparts that induced much less toxicity to the mice, thus suggesting a better therapeutic index.  
Incorporation of NIR-emitting dye in the polymer prodrugs structure successfully enabled 
the in vivo fate of drug-initiated synthesized PI nanoparticles to be monitored. We showed that 
biotinylated nanoparticles led to a delayed liver accumulation compared to non-biotinylated 
nanoparticles, indicating moderate stealth property likely due to hydrophilic TEG-Biot and the short 
EG chain. Also, ex vivo fluorescence imaging showed significant liver accumulation of both 
nanoparticles in agreement with in vivo imaging. It also suggested their accumulation into the 
tumors with a slightly higher amount of biotinylated nanoparticles than non-biotinylated 
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counterparts. Nonetheless, it did not result in an improved anticancer activity, which was assigned 
to a much slower Gem release in presence of Biot at the other polymer extremity.  
Whereas simplicity is a key aspect of polymer prodrug nanoparticles obtained from the 
“drug-initiated” method, their efficient targeting via simple surface functionalization of Gem-PI 
nanoparticles with biotin as a ligand was not sufficient to induce a significantly higher anticancer 
efficacy. This could be solved by either: (i) improving stealth properties and enhancing accessibility 
to biotin by using longer PEG chain than TEG and/or (ii) by using more selective targeting ligand 
with a greater affinity towards their targets such as peptide sequences or antibody fragments.  
In conclusion, this work showed for the first time the applicability of this simple 
construction method to in vivo imaging and cancer cell targeting, and might stimulate the design of 
new functional materials for biomedical applications.  
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